Our extensive product portfolio spans a wide range of therapeutic areas, including:
From chronic disease management to acute care, our diverse product portfolio addresses a wide range of therapeutic areas. We invest heavily in research and development to introduce innovative treatments that meet the evolving needs of patients and healthcare providers.
In addition to our pharmaceutical products, we offer a variety of support services to healthcare providers and patients, ensuring comprehensive care and better health outcomes.
Over the past six decades, Brivet HealthCare has carved a niche in numerous therapy areas. Today, we are the global leader in the Anti-Tuberculosis segment and continue to strengthen our anti-TB portfolio with the development of products for treating multi-drug resistant (MDR) tuberculosis.
We have played an effective role in reducing the disease burden across key therapy areas by providing access to affordable mission-critical medicines. In the US, more than 70% of our products rank amongst the top three products in their respective segments.
Brivet HealthCare’s biosimilar programme is focused on making high quality biologics affordable and accessible to patients across the globe. Our flagship product Etanercept, an injectable biologic, is currently available in Japan, India and the EU.
Feel free to connect with us for further information !